Want to see DNTH full AI Analyst Report?
Dianthus Therapeutics (DNTH) Income Statement
445 Followers
Dianthus Therapeutics Income Statement
Last quarter (Q3 2026), Dianthus Therapeutics's total revenue was $1.21M, an increase of 205.56% from the same quarter last year. In Q3, Dianthus Therapeutics's net income was $-46.64M. See Dianthus Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 2.04M | $ 6.24M | $ 2.83M | $ 6.42M | $ 1.48M | |
| $ 2.04M | $ 6.24M | $ 2.83M | $ 6.42M | $ 1.48M | |
| $ 179.97M | $ 108.10M | $ 51.00M | $ 36.12M | $ 14.56M | |
| Depreciation and Amortization | $ 428.00K | $ 412.00K | $ 355.00K | $ 147.00K | $ 2.02M |
| $ -161.91M | $ -84.56M | $ -43.20M | $ -28.33M | $ -11.09M | |
| $ -177.93M | $ -101.86M | $ -48.17M | $ -29.70M | $ -13.09M | |
| $ 15.60M | $ 16.89M | $ 4.62M | $ 1.23M | $ -23.00K | |
| $ -162.34M | $ -84.97M | $ -43.55M | $ -28.48M | $ -13.11M | |
| $ -162.34M | $ -84.97M | $ -43.55M | $ -28.48M | $ -13.11M | |
| Per Share Metrics | |||||
| Basic EPS | $ -4.20 | $ -2.55 | $ -8.45 | $ -7.60 | $ -3.82 |
| Diluted EPS | $ -4.20 | $ -2.55 | $ -8.45 | $ -7.60 | $ -3.82 |
| Weighted Average Shares Outstanding | 37.79M | 33.31M | 5.15M | 3.75M | 3.43M |
| Weighted Average Shares Outstanding (Diluted) | 37.79M | 33.31M | 5.15M | 3.75M | 3.43M |
Currency in USD
